93 related articles for article (PubMed ID: 20172200)
1. [The safety of perioperative bevacizumab use].
Mariani P
J Chir (Paris); 2010 Jan; 147 Suppl 1():S12-7. PubMed ID: 20172200
[TBL] [Abstract][Full Text] [Related]
2. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
[TBL] [Abstract][Full Text] [Related]
3. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
[TBL] [Abstract][Full Text] [Related]
4. [Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy?].
Zalinski S; Bigourdan JM; Vauthey JN
J Chir (Paris); 2010 Jan; 147 Suppl 1():S18-24. PubMed ID: 20172201
[TBL] [Abstract][Full Text] [Related]
5. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
[TBL] [Abstract][Full Text] [Related]
6. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
[TBL] [Abstract][Full Text] [Related]
7. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
[TBL] [Abstract][Full Text] [Related]
8. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.
Wicherts DA; de Haas RJ; Sebagh M; Saenz Corrales E; Gorden DL; Lévi F; Paule B; Azoulay D; Castaing D; Adam R
Br J Surg; 2011 Mar; 98(3):399-407. PubMed ID: 21254017
[TBL] [Abstract][Full Text] [Related]
9. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients.
Millet G; Truant S; Leteurtre E; Hebbar M; Zerbib P; Huet G; Boleslawski E; Pruvot FR
Ann Surg; 2012 Nov; 256(5):755-61; discussion 761-2. PubMed ID: 23095619
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
11. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.
Siperstein AE; Berber E; Ballem N; Parikh RT
Ann Surg; 2007 Oct; 246(4):559-65; discussion 565-7. PubMed ID: 17893492
[TBL] [Abstract][Full Text] [Related]
12. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.
Mahfud M; Breitenstein S; El-Badry AM; Puhan M; Rickenbacher A; Samaras P; Pessaux P; Lopez-Ben S; Jaeck D; Figueras J; Alain-Clavien P
World J Surg; 2010 Jan; 34(1):92-100. PubMed ID: 19838754
[TBL] [Abstract][Full Text] [Related]
13. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
van der Pool AE; Marsman HA; Verheij J; Ten Kate FJ; Eggermont AM; Ijzermans JN; Verhoef C
J Surg Oncol; 2012 Dec; 106(7):892-7. PubMed ID: 22552819
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy's hepatotoxicity: what is the impact on surgery?].
Pessaux P
J Chir (Paris); 2010 Jan; 147 Suppl 1():S7-S11. PubMed ID: 20172202
[TBL] [Abstract][Full Text] [Related]
15. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases.
Chiappa A; Bertani E; Makuuchi M; Zbar AP; Contino G; Viale G; Pruneri G; Bellomi M; Della Vigna P; Zampino MG; Fazio N; Travaini ML; Trifirò G; Corbellini C; Andreoni B
Hepatogastroenterology; 2009; 56(91-92):829-34. PubMed ID: 19621711
[TBL] [Abstract][Full Text] [Related]
17. Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based?
Bilchik AJ; Hecht JR
J Clin Oncol; 2008 Apr; 26(11):1786-8. PubMed ID: 18398144
[No Abstract] [Full Text] [Related]
18. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
19. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
August DA; Serrano D; Poplin E
J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
[TBL] [Abstract][Full Text] [Related]
20. [The role of perioperative chemotherapy in patients with resectable colorectal liver metastases].
Brouquet A; Mitry E; Benoist S
J Chir (Paris); 2010 Jan; 147 Suppl 1():S1-6. PubMed ID: 20172199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]